In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
In a trial of men who volunteered for PSA screening, detection of clinically insignificant tumors and benign findings were reduced when prostate biopsy was performed only in those with positive MRI results.
A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.